Radnostix Q1 net loss widens to $1.35 million; product sales drop 27% to $2.38 million

INTERNATIONAL ISOTOPES INC

INTERNATIONAL ISOTOPES INC

INIS

0.00
  • Radnostix posted a net loss of $1.35 million for the quarter ended March 31, 2026, widening from a net loss of $112,694 a year earlier.
  • Sale of Product fell 27% to $2.38 million, while gross profit dropped 43% to $1.15 million.
  • Operating expenses climbed 17% to $2.46 million, driven by higher professional fees, stock-based compensation, and research and development spending.
  • Theranostics Products sales declined 22% to $1.4 million on voluntary recalls, while Cobalt Products sales slid 87% to $9,739 amid a process hot-cell rehabilitation shutdown.
  • Calibration & Reference Products sales decreased 33% to $882,790 on prior-year catch-up demand tied to a cobalt-57 shortage, while Medical Device Products sales rose 69% to $89,113.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radnostix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-017906), on May 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.